The Asia Pacific is currently ranked third in terms of revenue from the depression drugs and devices market, where Inkwood research has quantified the expected growth rate of the antidepressants drugs, devices, and therapies market to be around 3.32% during the forecasting years of 2019-2027.

ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET FORECAST 2019-2027

Asia Pacific Antidepressants Drugs, Devices and Therapies Market by Antidepressants Drugs (Serotonin and Norepinephrine Reuptake Inhibitors (Snris), Tricyclic Antidepressants (Tcas), Monoamine Oxidase Inhibitors (Maois), Atypical Antidepressants, Selective Serotonin Reuptake Inhibitors, Benzodiazepines, Anticonvulsants, Beta-blockers, Other Antidepressants Drugs) by Devices (Deep Brain Stimulators, Fisher Wallace Stimulators, Transcranial Magnetic Stimulator, Other Devices) by Therapies (Cognitive Behavior Therapy (Cbt), Electroconvulsive Therapy (Ect), Rational Emotive Behavior Therapy (Rebt), Other Therapies) by Geography.

Request free sample

Report Summary

A key reason for the continuing rise in clinical depressive illness is that drugs do not necessarily “cure” the patient, and other therapies that can make the crucial difference are usually not in sufficient supply, especially in the developing countries of the Asia Pacific region, where alongside the availability issue, social stigma plays a role. For instance, the acceptance of the diagnosis of any form of mental illness is still considered a taboo in some of the Asia Pacific countries. The Asia Pacific is currently ranked third in terms of revenue from the depression drugs and devices market, where Inkwood research has quantified the expected growth rate of the antidepressants drugs, devices, and therapies market to be around 3.32% during the forecasting years of 2019-2027.

The economies of China, India, Japan, South Korea, Australia and the remaining countries constituting the Rest of Asia Pacific segment are majorly influencing the market growth in the APAC region. With a strongly emerging generic drugs market in China and India, the market is expected to witness an upward shift. The Asia Pacific has over 100 million patients suffering from various mental health diseases. The countries with very poor mental healthcare systems have very low levels of awareness regarding depression. There has been a significant increase in the sales of antidepressants in the last few years because of the rising usage of antidepressant drugs is changing lifestyles of people where every age group suffer from depression.

The major competing market players in the APAC region are F. Hoffmann-La Roche Ltd., Mayo Clinic, Boehringer Ingelheim GmbH, Abbot Laboratories, H. Lundbeck AS, Allergan PLC, Brainsway, Eli Lilly and Company, Neuronetics, GlaxoSmithKline and Pfizer.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP-DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
  - SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IS THE DOMINANT DRUG IN ANTIDEPRESSANTS MARKET
  - DEEP BRAIN STIMULATOR IS EXPECTED TO GROW FAST AMONG OTHER DEVICES OVER THE FORECAST PERIOD
  - COGNITIVE BEHAVIOR THERAPY (CBT) IS THE LARGEST CONTRIBUTOR TO THE ANTIDEPRESSANTS THERAPIES MARKET

MARKET DYNAMICS
- MARKET DEFINITION & SCOPE
- MARKET DRIVERS
  - RISE IN THE NUMBER OF DEPRESSION PATIENTS
  - INCREASE IN AGING POPULATION
  - RISING CONSCIOUSNESS OF DEPRESSION AS A MEDICAL DISORDER
  - SURGE IN SALES OF ANTIDEPRESSANTS
- MARKET RESTRAINTS
  - HIGH COST OF DEPRESSION THERAPY
  - PATENT EXPIRATION FACED BY THE COMPANIES
  - DELAY IN PRODUCT LAUNCHES
- MARKET OPPORTUNITIES
  - HUGE MARKET POTENTIAL
  - MORE PREFERENCE FOR PERSONNEL THERAPY & DEVICE TREATMENT
- MARKET CHALLENGES
  - STIFF COMPETITION FROM THE GENERIC DRUGMAKERS

MARKET BY ANTIDEPRESSANTS DRUGS
- SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
- TRICYCLIC ANTIDEPRESSANTS (TCAs)
- MONOAMINE OXIDASE INHIBITORS (MAOIs)
- ATYPICAL ANTIDEPRESSANTS
- SELECTIVE SEROTONIN REUPTAKE INHIBITORS
- BENZODIAZEPINES
- ANTICONVULSANTS
- BETA-BLOCKERS
- OTHER ANTIDEPRESSANTS DRUGS
MARKET BY DEVICES
- DEEP BRAIN STIMULATORS
- FISHER WALLACE STIMULATORS
- TRANSCRANIAL MAGNETIC STIMULATOR
- OTHER DEVICES
MARKET BY THERAPIES
- COGNITIVE BEHAVIOR THERAPY (CBT)
- ELECTROCONVULSIVE THERAPY (ECT)
- RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
- OTHER THERAPIES
KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
  - THREAT OF NEW ENTRANTS
  - THREAT OF SUBSTITUTE
  - BARGAINING POWER OF SUPPLIERS
  - BARGAINING POWER OF BUYERS
  - THREAT OF COMPETITIVE RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- VALUE CHAIN ANALYSIS
  - FOR DRUGS
  - FOR DEVICES
- KEY BUYING CRITERIA
GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
  - INDIA
  - CHINA
  - JAPAN
  - SOUTH KOREA
  - AUSTRALIA
  - REST OF ASIA PACIFIC (RoAPAC)

COMPETITIVE LANDSCAPE
- MARKET SHARE ANALYSIS
- COMPANY PROFILE
  - ABBOT LABORATORIES
  - ALLERGAN PLC
  - BOEHRINGER INGELHEIM GMBH
  - BRAINSWAY
  - ELI LILLY AND COMPANY
  - HOFFMANN-LA ROCHE LTD.
  - GLAXOSMITHKLINE
  - LUNDBECK AS
  - MAYO CLINIC
  - NEURONETICS
  - PFIZER

TABLE LIST

TABLE 1 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)

TABLE 2 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ANTIDEPRESSANTS DRUGS, 2019-2027, (IN $ MILLION)

TABLE 3 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY DEVICES, 2019-2027, (IN $ MILLION)

TABLE 4 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY THERAPIES, 2019-2027, (IN $ MILLION)

TABLE 5 OPPORTUNITY MATRIX

TABLE 6 VENDOR LANDSCAPE

TABLE 7 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)

FIGURE LIST

FIGURE 1 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET SHARE, BY DRUGS 2018 & 2027 (%)

FIGURE 2 SNRIs MARKET, 2019 – 2027 (IN $ MILLION)

FIGURE 3 DEEP BRAIN STIMULATORS MARKET, 2019-2027 (IN $ MILLION)

FIGURE 4 COGNITIVE BEHAVIOR THERAPY (CBT) MARKET (IN $ MILLION)

FIGURE 5 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COGNITIVE BEHAVIOR THERAPY (CBT), 2019-2027, (IN $ MILLION)

FIGURE 6 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ELECTROCONVULSIVE THERAPY (ECT), 2019-2027, (IN $ MILLION)

FIGURE 7 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT), 2019-2027, (IN $ MILLION)

FIGURE 8 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, OTHER THERAPIES, 2019-2027, (IN $ MILLION)

FIGURE 9 PORTER’S FIVE FORCE MODEL

FIGURE 10 VALUE CHAIN OF ANTIDEPRESSANT DRUGS

FIGURE 11 VALUE CHAIN ANALYSIS FOR DEVICE MARKET

FIGURE 12 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, REGIONAL OUTLOOK, 2018 & 2027, (%)

FIGURE 13 INDIA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

FIGURE 14 CHINA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

FIGURE 15 JAPAN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

FIGURE 16 SOUTH KOREA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

FIGURE 17 AUSTRALIA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

FIGURE 18 REST OF ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

FIGURE 19 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2018

Segmentation

GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
  - INDIA
  - CHINA
  - JAPAN
  - SOUTH KOREA
  - AUSTRALIA
  - REST OF ASIA PACIFIC (RoAPAC)

MARKET BY ANTIDEPRESSANTS DRUGS
- SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
- TRICYCLIC ANTIDEPRESSANTS (TCAs)
- MONOAMINE OXIDASE INHIBITORS (MAOIs)
- ATYPICAL ANTIDEPRESSANTS
- SELECTIVE SEROTONIN REUPTAKE INHIBITORS
- BENZODIAZEPINES
- ANTICONVULSANTS
- BETA-BLOCKERS
- OTHER ANTIDEPRESSANTS DRUGS
MARKET BY DEVICES
- DEEP BRAIN STIMULATORS
- FISHER WALLACE STIMULATORS
- TRANSCRANIAL MAGNETIC STIMULATOR
- OTHER DEVICES
MARKET BY THERAPIES
- COGNITIVE BEHAVIOR THERAPY (CBT)
- ELECTROCONVULSIVE THERAPY (ECT)
- RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
- OTHER THERAPIES